Allergan Inc. posted an 8.3 percent rise in profit last quarter, despite lower projections and competition from Dysport, the latest Botox alternative.
Surprisingly, both pharmaceuticals, Allergan and Medicis, grew during the third quarter, and analysts partially attribute their success to the popular cosmetic treatments.
According to CNN Money, revenues for Dysport manufacturer Medicis last quarter were 30 percent above last year’s figures. “We are encouraged by the positive physician and patient response to DYSPORT,” said Medicis CEO Jonah Shacknai.
To the surprise of many industry experts, Dysport didn’t manage to hurt sales of Botox. Aided by a 3 percent increase in Botox sales, “Allergan’s third quarter profit rose 8.3 percent” reports the Wall Street Journal. New treatment applications are also moving toward FDA approval, which could drive sales further.
Although there’s been moderate interest about Dysport in Tucson, Botox still dominates with much stronger brand awareness.
Tags: Botox
